Here are five key notes:
1. The agreements cover the development of bone grafting therapies based on the use of BioTime’s proprietary PureStem human embryonic progenitor cell technology.
2. Under the terms of the development agreement, Heraeus Medical will make an initial $1 million upfront payment to OrthoCyte, and additional payments upon OrthoCyte’s attainment of certain product development milestones.
3. OrthoCyte will be responsible for product development and initially for manufacturing.
4. Heraeus Medical will be responsible for worldwide sales of new and existing products.
5. Pursuant to the terms of the license agreement, OrthoCyte has licensed certain technology to Heraeus, and Heraeus has licensed certain technology to OrthoCyte.
More articles on devices:
EOS imaging acquires rights to new scoliosis prognosis technology: 5 key notes
Medtronic pays $500M US tax charge for Ireland move: 5 things to know
5 new device launches & releases
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
